RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Recommendation of "Hold" by Brokerages

RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has received an average rating of "Hold" from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $4.00.

Separately, HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of RAPT Therapeutics in a research note on Monday, March 10th.

Institutional Investors Weigh In On RAPT Therapeutics

Several large investors have recently added to or reduced their stakes in RAPT. Simplicity Wealth LLC purchased a new stake in shares of RAPT Therapeutics during the first quarter worth $25,000. Picton Mahoney Asset Management increased its holdings in RAPT Therapeutics by 994.4% during the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company's stock worth $26,000 after purchasing an additional 14,697 shares during the period. JPMorgan Chase & Co. raised its position in RAPT Therapeutics by 298.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company's stock valued at $34,000 after purchasing an additional 25,130 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of RAPT Therapeutics in the 4th quarter valued at about $63,000. Finally, Sei Investments Co. acquired a new position in shares of RAPT Therapeutics during the fourth quarter worth about $64,000. 99.09% of the stock is owned by hedge funds and other institutional investors.

RAPT Therapeutics Price Performance

RAPT traded down $0.03 during trading hours on Friday, reaching $0.77. The company's stock had a trading volume of 734,481 shares, compared to its average volume of 1,265,212. The stock has a market cap of $101.65 million, a PE ratio of -0.28 and a beta of -0.04. RAPT Therapeutics has a fifty-two week low of $0.75 and a fifty-two week high of $4.83. The business's 50-day moving average is $1.03 and its 200-day moving average is $1.25.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.23. Analysts expect that RAPT Therapeutics will post -2.14 EPS for the current year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.